It’s only fair to share… LANRAPLENIB GS-9876 Phase II, GILEAD Phase II Gilead Cutaneous lupus erythematosus Rheumatoid arthritis Sjogren syndrome GS-9876 LANRAPLENIB Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)- 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo|1,2-a]pyrazin-8-amine 6-(6-Amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)imidazo(1,2-a)pyrazin-8-amine Molecular Weight 443.50 Formula C₂₃H₂₅N₉O CAS No. 1800046-95-0 Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) …